β-Phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype

Biochemical Pharmacology

Volumn 85, Issue 4, 2013, Pages 486-496

  Wu, Wen Jing ^a   Zhang, Yan ^a   Zeng, Zhao Lei ^a   Li, Xiao Bing ^a   Hu, Kai Shun ^c   Luo, Hui Yan ^a   Yang, Jing ^a   Huang, Peng ^a,b   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS   (United States)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemo resistance; Chemotherapy; EMT; Glutathione; PEITC

Indexed keywords

CISPLATIN; GLUTATHIONE; OXALIPLATIN; PHENETHYL ISOTHIOCYANATE; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; COLONY FORMATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; ISOTHIOCYANATES; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS;

EID: 84872679732     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.11.017     Document Type: Article

References (47)

1. B. Rosenberg, L. VanCamp, J.E. Trosko, and V.H. Mansour Platinum compounds: a new class of potent antitumour agents Nature 222 1969 385 386
2. D.R. Spigel, and F.A. Greco Chemotherapy in metastatic and locally advanced non-small cell lung cancer Semin Surg Oncol 21 2003 98 110
3. P.A. Vasey, J. Paul, A. Birt, E.J. Junor, N.S. Reed, and R.P. Symonds Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group J Clin Oncol 17 1999 2069 2080
4. S.W. Kim, C. Suh, S.D. Lee, W.S. Kim, D.S. Kim, and W.D. Kim Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer Lung Cancer 41 2003 221 226
5. S. Giacchetti, B. Perpoint, R. Zidani, N. Le Bail, R. Faggiuolo, and C. Focan Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 2000 136 147
6. P.V. Korita, T. Wakai, Y. Shirai, Y. Matsuda, J. Sakata, and M. Takamura Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma Oncol Rep 23 2010 965 972
7. J. Wang, J.Y. Zhou, L. Zhang, and G.S. Wu Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells Cell Cycle 8 2009 3191 3198
8. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, and O. Kepp Molecular mechanisms of cisplatin resistance Oncogene 2011
9. K. Koike, T. Kawabe, T. Tanaka, S. Toh, T. Uchiumi, and M. Wada A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells Cancer Res 57 1997 5475 5479
10. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat Rev Cancer 5 2005 275 284
11. S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, and A.B. Hjelmeland Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
12. S. Ma, T.K. Lee, B.J. Zheng, K.W. Chan, and X.Y. Guan CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway Oncogene 27 2008 1749 1758
13. G.G. Wulf, R.Y. Wang, I. Kuehnle, D. Weidner, F. Marini, and M.K. Brenner A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia Blood 98 2001 1166 1173
14. K. He, T. Xu, and A. Goldkorn Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype Mol Cancer Ther 10 2011 938 948
15. S. Ishida, F. McCormick, K. Smith-McCune, and D. Hanahan Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator Cancer Cell 17 2010 574 583
16. M. Yashiro, T. Inoue, N. Nishioka, T. Matsuoka, C.R. Boland, and K. Hirakawa Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma Ann Surg Oncol 16 2009 2926 2935
17. Z.H. Li, M.Z. Qiu, Z.L. Zeng, H.Y. Luo, W.J. Wu, and F. Wang Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC) J Transl Med 10 2012 21
18. H. Tang, Y.J. Liu, M. Liu, and Li X. Establishment gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP Anticancer Drugs 18 2007 633 639
19. M. Yamasaki, T. Makino, T. Masuzawa, Y. Kurokawa, H. Miyata, and S. Takiguchi Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma Br J Cancer 104 2011 707 713
20. A.K. Tiwari, K. Sodani, C.L. Dai, C.R. Ashby Jr., and Z.S. Chen Revisiting the ABCs of multidrug resistance in cancer chemotherapy Curr Pharm Biotechnol 12 2011 570 594
21. Z. Shi, A.K. Tiwari, S. Shukla, R.W. Robey, S. Singh, and I.W. Kim Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance Cancer Res 71 2011 3029 3041
22. H.H. Chen, and M.T. Kuo Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy Met Based Drugs 2010 2010
23. M. Dean, A. Rzhetsky, and R. Allikmets The human ATP-binding cassette (ABC) transporter superfamily Genome Res 11 2001 1156 1166
24. K.S. Yao, A.K. Godwin, S.W. Johnson, R.F. Ozols, P.J. O'Dwyer, and T.C. Hamilton Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines Cancer Res 55 1995 4367 4374
25. G.V. Dedoussis, and N.K. Andrikopoulos Glutathione depletion restores the susceptibility of cisplatin-resistant chronic myelogenous leukemia cell lines to Natural Killer cell-mediated cell death via necrosis rather than apoptosis Eur J Cell Biol 80 2001 608 614
26. T. Ishikawa, and F. Ali-Osman Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance J Biol Chem 268 1993 20116 20125
27. H.H. Chen, I.S. Song, A. Hossain, M.K. Choi, Y. Yamane, and Z.D. Liang Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1 Mol Pharmacol 74 2008 697 704
28. M. Diehn, R.W. Cho, N.A. Lobo, T. Kalisky, M.J. Dorie, and A.N. Kulp Association of reactive oxygen species levels and radioresistance in cancer stem cells Nature 458 2009 780 783
29. K.L. Cheung, and A.N. Kong Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention AAPS J 12 2010 87 97
30. S.S. Hecht Chemoprevention by isothiocyanates J Cell Biochem Suppl 22 1995 195 209
31. J. Szumilo Natural compounds in chemoprevention of esophageal squamous cell tumors - experimental studies Pol Merkur Lekarski 26 2009 156 161
32. D. Trachootham, H. Zhang, W. Zhang, L. Feng, M. Du, and Y. Zhou Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism Blood 112 2008 1912 1922
33. D. Trachootham, Y. Zhou, H. Zhang, Y. Demizu, Z. Chen, and H. Pelicano Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate Cancer Cell 10 2006 241 252
34. Y. Hu, W. Lu, G. Chen, H. Zhang, Y. Jia, and Y. Wei Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate Blood 116 2010 2732 2741
35. S. Batra, R.P. Sahu, P.K. Kandala, and S.K. Srivastava Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells Mol Cancer Ther 9 2010 1596 1608
36. P. Gupta, and S.K. Srivastava Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models BMC Med 10 2012 80
37. D. Xiao, and S.V. Singh Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo Pharm Res 27 2010 722 731
38. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach Nat Rev Drug Discov 8 2009 579 591
39. X.B. Lv, F. Xie, K. Hu, Y. Wu, L.L. Cao, and X. Han Damaged DNA-binding protein 1 (DDB1) interacts with Cdh1 and modulates the function of APC/CCdh1 J Biol Chem 285 2010 18234 18240
40. A.J. Di Pasqua, C. Hong, M.Y. Wu, E. McCracken, X. Wang, and L. Mi Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring isothiocyanates Chem Res Toxicol 23 2010 1307 1309
41. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat Rev Drug Discov 4 2005 307 320
42. B. Stordal, N. Pavlakis, and R. Davey Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review Cancer Treat Rev 33 2007 347 357
43. F. Ishikawa, S. Yoshida, Y. Saito, A. Hijikata, H. Kitamura, and S. Tanaka Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region Nat Biotechnol 25 2007 1315 1321
44. J.E. Visvader, and G.J. Lindeman Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nat Rev Cancer 8 2008 755 768
45. X. Wang, S. Govind, S.P. Sajankila, L. Mi, R. Roy, and F.L. Chung Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin Mol Nutr Food Res 55 2011 1572 1581
46. M. d'Avenia, A. Rosati, M.A. Belisario, M. Torino, G. Torino, and M.C. Turco The expression of the pro-apoptotic gene Air is inducible in human pancreatic adenocarcinoma cells J Cell Physiol 226 2011 2207 2212
47. H.H. Bailey, R.T. Mulcahy, K.D. Tutsch, R.Z. Arzoomanian, D. Alberti, and M.B. Tombes Phase I clinical trial of intravenous l-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione J Clin Oncol 12 1994 194 205